

**Subject: Specialised Services Circular (SSC)**  
**Sent on behalf of: Chair of the SW Specialised Service Circular Group**

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2799	NHS England Clinical Commissioning Policy: Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England, 2025	All South West Acute Trusts

**Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? **No****

**For all other South West region trusts this is for information only.**

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

**All Chief Executives**

**All Medical Directors**

**All Chief Pharmacists**

Specialised Commissioning South West  
NHS England  
100 Temple Street  
Bristol  
BS1 6AG  
Email: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

31 March 2025

Dear Colleagues

**Re: NHS England Clinical Commissioning Policy: Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England, 2025**

I am writing to advise you that the NHS England (NHSE) Clinical Commissioning Policy (CCP) for the use of therapeutic immunoglobulin (Ig) in England has recently been updated. This version supersedes all previous versions of the CCP. Amendments are detailed on the accompanying change form. In particular, these include:

- Updated clinical evidence for secondary antibody deficiency – long term use;
- Guidance for use of immunoglobulin in children where plasma exchange may be problematic for logistical reasons;
- Updated UKHSA guidance for measles, suspected tetanus case, tetanus prone injury (prophylaxis) and varicella zoster;
- New indication added for scleromyxedema;
- Additional clarity regarding dosing optimisation in neurology for maintenance.

The CCP can be found at: [NHS England » Clinical commissioning policy for the use of therapeutic immunoglobulin \(Ig\) England \(2025\)](#)

Trusts will be required to:

- Work with Sub Regional Immunoglobulin Assessment Panels (SRIAPs) to ensure that the Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England, 2025 is fully implemented;
- Ensure that all relevant clinical teams are aware of the updated document and working to the guidelines;

In addition:


- Trusts must ensure that only invoices for the drug procurement costs of immunoglobulin are invoiced to NHSE and that they are also submitting complete and accurate information via the minimum dataset (MDS). All other on costs are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust

invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.

- Patients must be registered using the MDSAS prior approval process and prior panel approval from Sub Regional Immunoglobulin Assessment Panels must be secured before treatment commences, except where the guidance specifies otherwise.
- Payment of Trust invoices will be contingent on MDSAS registration, the MDS being completed and this information being made available in a timely way.
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

With best wishes,



Emma Redfern  
Medical Director NHS England South West  
Region



Tracey Williams  
Principal Pharmacist